Update on financial status
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Inside Information: Update on financial status · Further cash preservation extends runway into Q3/2024 · Understanding on conditional Waiver Extension reached with IPF, covering the Company until end of June 2024 to conduct the planned activities securing the further development of bexmarilimab in HMA-failed MDS Company announcement, 30 April 2024 at 16:00 (EEST) / 14:00 (BST) / 9:00 AM (EDT) Inside information TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-